Ultragenyx: Great Medicine, Good Execution, Stagnant Stock [Seeking Alpha]
Ultragenyx Pharmaceutical Inc. (RARE)
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ultragenyx.com/investor-relations
Company Research
Source: Seeking Alpha
nambitomoAlthough I believe in the company, Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREindications, and these together pull in around a third of a billion dollars every year (by 2021 figures). They have two phase 3 drugs, 3 in phase 2, and couple more in phase 1. They have a huge amount of cash. The short interest is also low. So why does this stock keep hitting new lows?One reason, like I said, is lack of major near-term catalysts. There are no PDUFAs or pivotal trial toplining in the next few months.Another major reason is a few hiccups in some of their trials. Their latest stage candidate - as mentioned on their website - is UX111 (formerly ABO-102), a gene therapy in an ongoing pivotal Transpher A trial in patients with Sanfilippo syndrome type A (MPS IIIA). I see fromclinicaltrials.govstudyOn the issue of differences in scoring, hereâ??s a discussion from theirearnings callMaurice RaycroftGot it. And also for Angelman, there's been some discussion on potential CGI score discordan
Show less
Read more
Impact Snapshot
Event Time:
RARE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RARE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RARE alerts
High impacting Ultragenyx Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
RARE
News
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its price target raised by analysts at TD Cowen from $59.00 to $61.00. They now have a "buy" rating on the stock.MarketBeat
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $77.00 price target on the stock.MarketBeat
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study [Yahoo! Finance]Yahoo! Finance
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.MarketBeat
RARE
Earnings
- 2/15/24 - Beat
RARE
Sec Filings
- 4/19/24 - Form 4
- 4/18/24 - Form 4
- 4/15/24 - Form 8-K
- RARE's page on the SEC website